Kolexia
Allaire Manon Gastro-entérologie
Allaire Manon
Gastro-entérologie
Hôpital Pitie Salpetriere
Paris, France
172 Activités
187 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Fibrose Cirrhose du foie Hypertension portale Hypertension artérielle Maladies du foie Hémorragie

Collaborateurs

Voir plus
Thabut Dominique
Thabut Dominique
Hôpital Pitie Salpetriere, Paris, France
Nault Jean-Charles
Nault Jean-Charles
Hôpital Jean Verdier, Bondy, France
Carrie Nathalie
Carrie Nathalie
Hôpital Jean Verdier, Bondy, France
Dao Manh Thong
Dao Manh Thong
Hôpital Côte de Nacre, Caen, France

Industries

Voir plus
Roche
7 collaboration(s)
Dernière en 2022
Gilead
3 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2023
Ipsen
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Comment on Wu et al. Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma. 2023, , 2480.
Cancers   04 février 2024
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Liver international : official journal of the International Association for the Study of the Liver   30 janvier 2024
Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
Clinics and research in hepatology and gastroenterology   06 janvier 2024
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Nature communications   14 décembre 2023
Portal-hypertension features are associated with ascites occurrence and survival in patients with hepatocellular carcinoma treated by external radiotherapy.
United European gastroenterology journal   29 novembre 2023
The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
Journal of gastroenterology and hepatology   21 novembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab.
Hepatology (Baltimore, Md.)   23 octobre 2023
Complete response with sorafenib after immune-induced hepatitis with atezolizumab/bevacizumab for advanced hepatocellular carcinoma, synergic effect?
Clinics and research in hepatology and gastroenterology   27 septembre 2023
Difficulties in assessing portal hypertension in case of HVB-HVD co infection.
Clinics and research in hepatology and gastroenterology   27 septembre 2023